Constellation Pharmaceuticals to Host Analyst / Investor Event to Discuss Update of MANIFEST Clinical Trial for CPI-0610

Rhea-AI Summary

Constellation (NASDAQ: CNST) will host a virtual analyst/investor event on June 12 at 8:00 AM EDT to discuss data from the MANIFEST clinical trial for CPI-0610 at the European Hematology Association meeting. The agenda includes an overview of myelofibrosis and the potential impact of CPI-0610, alongside a review of the clinical trial data. The MANIFEST trial focuses on myelofibrosis treatment using CPI-0610, evaluating its effects in various patient cohorts. This event will be webcast live, providing an opportunity for investors to engage in a Q&A session.

Positive

• CPI-0610 showing potential in treating myelofibrosis through the MANIFEST trial.
• The event provides clarity on trial data, which may boost investor confidence.

Negative

• No interim results or specific data points from the MANIFEST trial reported, leaving uncertainty.

News Market Reaction – CNST

+0.39%

1 alert

+0.39% News Effect

On the day this news was published, CNST gained 0.39%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a virtual analyst/investor event and conference call on June 12 at 8:00 AM EDT to discuss the data from three posters on the MANIFEST clinical trial for CPI-0610 being presented at the European Hematology Association meeting.

The agenda of the event will include:

• An overview of myelofibrosis (MF) and the potential impact of Constellation’s BET inhibitor CPI-0610 in treating MF
• A review of the data from the MANIFEST clinical trial presented in the EHA posters
• A live question-and-answer session

The event will be webcast live and can be accessed on the Investor Relations section of Constellation’s website at http://ir.constellationpharma.com/events-and-presentations/events.  To participate in the live question-and-answer session, please dial (877) 473-2077 (domestic) or (661) 378-9662 (international) and refer to conference ID 6275774.

About MANIFEST

MANIFEST is an open-label Phase 2 clinical trial of CPI-0610 in patients with myelofibrosis (MF), a rare cancer of the bone marrow that disrupts the body’s normal production of blood cells. Constellation is evaluating CPI-0610 in combination with ruxolitinib in JAK-inhibitor-naïve MF patients (Arm 3), with a primary endpoint of the proportion of patients with a ≥35% spleen volume reduction from baseline (SVR35) after 24 weeks of treatment. Constellation is also evaluating CPI-0610, either as a monotherapy in patients who are resistant to, intolerant of, or ineligible for ruxolitinib and no longer on the drug (Arm 1), or as add-on therapy in combination with ruxolitinib in patients with a sub-optimal response to ruxolitinib or MF progression (Arm 2). Patients in Arms 1 and 2 are being stratified based on TD status. The primary endpoint for the patients in cohorts 1A and 2A, who were TD at baseline, is conversion to TI for 12 consecutive weeks. The primary endpoint for the patients in cohorts 1B and 2B, who were not TD at baseline, is the proportion of patients with a ≥35% spleen volume reduction from baseline after 24 weeks of treatment.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer.  The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitors CPI-1205 and CPI0209 for the treatment of metastatic castration-resistant prostate cancer and other cancers.  The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates. 

Contact

Kia Khaleghpour, PhD
Vice President, Investor Relations and Communications
Constellation Pharmaceuticals
+1 617-844-6859
kia.khaleghpour@constellationpharma.com

Ronald Aldridge 
Investor Relations
Constellation Pharmaceuticals +1 617-714-0539
ron.aldridge@constellationpharma.com

Lauren Arnold
Media Relations
MacDougall Biomedical Communications
+1 781-235-3060
larnold@macbiocom.com

FAQ

What is the purpose of the MANIFEST clinical trial for CNST?

The MANIFEST trial aims to evaluate the efficacy of CPI-0610 in treating myelofibrosis.

What are the expected outcomes from the upcoming event on June 12 for CNST?

The event will present data from the MANIFEST trial and provide an overview of myelofibrosis treatment.

When is the virtual analyst/investor event for CNST scheduled?

The event is scheduled for June 12 at 8:00 AM EDT.

How will the MANIFEST trial data impact the future of CNST?

Positive data from the trial could enhance investor confidence and influence stock performance.

What are the primary endpoints of the MANIFEST clinical trial for CNST?

Endpoints include spleen volume reduction and treatment responses in various patient cohorts.